ACRS Aclaris Therapeutics, Inc. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
ACRS Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$3.24
Analyst Target
$8.0
+146.9%
Upside
52W High
$4.89
52W Low
$1.05
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Feb 21, 2026
Market cap
$351.04M
P/E
N/A
ROE
-113.2%
Profit margin
N/A
Debt/Equity
0.02
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
85%
Analysis Accuracy
ACRS exhibits severe financial distress, reflected in a Piotroski F-Score of 1/9—indicating weak operational and financial health—while lacking an Altman Z-Score, which raises unquantified bankruptcy risk. The company reports negative profitability across all margins, with a staggering -516.79% operating margin and -113.23% ROE, signaling deep operational inefficiency. Despite a modest 6M return of +80.0%, the stock has declined 85.9% over 5 years, and revenue is contracting at -24.1% YoY. The absence of a Graham Number and intrinsic value estimate, combined with a high Price/Sales of 22.30, suggests the stock trades at a significant premium to fundamental value, likely driven by speculative growth hopes rather than earnings sustainability.
Key Strengths
Strong 6-month price performance (+80.0%) indicates short-term momentum
High current and quick ratios (3.92) suggest strong liquidity and short-term financial resilience
Low debt/equity ratio (0.02) implies minimal leverage risk
Recent quarter showed positive EPS surprise (+14.3%) and improving Q/Q EPS growth (+7.7%)
Analyst target price of $8.00 implies a 147% upside from current levels, indicating some growth optimism
Key Risks
Piotroski F-Score of 1/9 signals extreme financial weakness and poor operational performance
Negative operating margin (-516.79%) and ROE (-113.23%) indicate severe unprofitability
Revenue declining at -24.1% YoY, with no signs of recovery in growth trajectory
No dividend, no free cash flow, and no earnings history to support valuation
Lack of Altman Z-Score and absence of Graham Number or intrinsic value suggest no reliable valuation anchor
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
21
Weak
20
45
25
15
0
AI Verdict
High Risk
Key drivers: Extremely low Piotroski F-Score (1/9), Negative profitability and declining revenue, High valuation multiples without earnings support, Lack of financial health metrics (Altman Z-Score), Speculative growth expectations driving price
Confidence
88%
Value
20/100
Ref P/E, PEG, Graham Number
Positives
- Low debt/equity (0.02) reduces financial risk
- High current ratio (3.92) indicates strong liquidity
Watchpoints
- No Graham Number or intrinsic value estimate available
- Price/Sales of 22.30 is extremely high for a loss-making company
- Forward P/E of -5.89 indicates no earnings visibility
- No free cash flow or operating cash flow data
Future
45/100
Ref Growth rates
Positives
- Analyst target price of $8.00 implies strong growth expectations
- Recent EPS surprise of +14.3% and positive Q/Q EPS growth (+7.7%) suggest potential improvement
- 6-month return of +80.0% indicates market optimism
Watchpoints
- Revenue growth is -24.1% YoY, indicating ongoing business contraction
- No forward earnings guidance or growth trajectory beyond short-term EPS trends
- Historical earnings volatility and large negative surprises (e.g., -1275%)
Past
25/100
Ref Historical trends
Positives
- Consistent earnings reporting over 25 quarters shows operational continuity
- Some quarters beat estimates (e.g., +14.3%, +24.4%)
Watchpoints
- Most recent quarter missed by -169.3% (2025-02-27)
- Historical EPS surprises include extreme negative deviations (e.g., -1275%)
- 5-year price decline of -85.9% reflects long-term underperformance
Health
15/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Very low debt/equity (0.02) and high current ratio (3.92) suggest strong balance sheet liquidity
- No debt obligations reported
Watchpoints
- Piotroski F-Score of 1/9 is among the weakest possible, indicating severe financial distress
- No Altman Z-Score available, which is a red flag for bankruptcy risk
- Negative ROE (-113.23%) and ROA (-22.98%) show capital is being destroyed
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend strength is 0/100, indicating no income component
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$3.24
Analyst Target
$8.0
Upside/Downside
+146.9%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ACRS and closest competitors.
Updated 2026-02-20
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ACRS
Aclaris Therapeutics, Inc.
Primary
|
-85.9% | -74.8% | +40.3% | +80.0% | -26.7% | +1.6% |
|
AKBA
Akebia Therapeutics, Inc.
Peer
|
-63.3% | +88.4% | -43.1% | -61.8% | -20.0% | 0.0% |
|
BNR
Burning Rock Biotech Limited
Peer
|
-89.9% | +6.9% | +414.2% | +415.7% | +65.3% | +9.6% |
|
AQST
Aquestive Therapeutics, Inc.
Peer
|
-42.6% | +262.8% | +3.5% | -21.9% | -45.7% | -2.1% |
|
AMRN
Amarin Corporation plc
Peer
|
-91.1% | -66.3% | +29.4% | -1.6% | +5.1% | -1.1% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-5.89
PEG Ratio
N/A
P/B Ratio
2.92
P/S Ratio
22.3
EV/Revenue
16.35
EV/EBITDA
-3.92
Market Cap
$351.04M
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-516.79%
Gross Margin
-275.68%
ROE
-113.23%
ROA
-22.98%
Growth
Revenue and earnings growth rates
Revenue Growth
-24.1%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.02
Low debt
Current Ratio
3.92
Strong
Quick Ratio
3.92
Excellent
Cash/Share
$0.89
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-26
$N/A
2025-11-06
$-0.12
+14.3% surprise
2025-08-07
$-0.13
-1.3% surprise
2025-05-08
$-0.12
Healthcare Sector Comparison
Comparing ACRS against 146 companies in the Healthcare sector
(11 bullish, 60 neutral, 75 bearish)
Return on Equity (ROE)
-113.23%
This Stock
vs
-56.86%
Sector Avg
+99.1%
(Excellent)
Debt to Equity
0.02
This Stock
vs
2.68
Sector Avg
-99.3%
(Less Debt)
Revenue Growth
-24.1%
This Stock
vs
62.23%
Sector Avg
-138.7%
(Slower)
Current Ratio
3.92
This Stock
vs
3.45
Sector Avg
+13.8%
(Better)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ACRS
Aclaris Therapeutics, Inc.
|
BEARISH | $351.04M | - | -113.2% | -% | $3.24 | |
|
AKBA
Akebia Therapeutics, Inc.
|
NEUTRAL | $360.9M | - | -% | -7.1% | $1.36 | |
|
BNR
Burning Rock Biotech Limited
|
BEARISH | $377.58M | - | -20.2% | -22.5% | $35.07 | |
|
AQST
Aquestive Therapeutics, Inc.
|
BEARISH | $395.29M | - | -% | -158.9% | $3.24 | |
|
AMRN
Amarin Corporation plc
|
BEARISH | $306.69M | - | -17.4% | -38.0% | $14.75 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-03 | WALKER NEAL | Chief Executive Officer | Stock Award | 63,475 | - |
| 2026-02-03 | LOEROP JAMES | Officer | Stock Award | 20,875 | - |
| 2026-02-03 | BALTHASER KEVIN J | Chief Financial Officer | Stock Award | 22,025 | - |
| 2026-02-03 | DAVIS HUGH M. | President | Stock Award | 18,675 | - |
| 2026-01-30 | LOEROP JAMES | Officer | Stock Award | 33,500 | - |
| 2026-01-30 | BALTHASER KEVIN J | Chief Financial Officer | Stock Award | 14,750 | - |
| 2026-01-02 | WALKER NEAL | Chief Executive Officer | Stock Award | 29,150 | - |
| 2026-01-02 | LOEROP JAMES | Officer | Stock Award | 91,900 | - |
| 2026-01-02 | BALTHASER KEVIN J | Chief Financial Officer | Stock Award | 94,450 | - |
| 2025-12-02 | DAVIS HUGH M. | President | Stock Award | 26,750 | - |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
7 analysts
HC Wainwright & Co.
2026-01-28
Buy
Buy
HC Wainwright & Co.
2026-01-21
Buy
Buy
HC Wainwright & Co.
2025-10-20
Buy
Buy
Past News Coverage
Recent headlines mentioning ACRS from our newsroom.
Newest → oldest
No matching news yet.